HCA Healthcare
HCA
$372.13
+2.85%
HCA Healthcare, Inc. is the largest for-profit operator of acute-care hospitals and outpatient facilities in the United States, with a network of 190 hospitals and over 2,500 sites across 19 states and a small international presence. The company is a dominant market leader in its geographic footprint, leveraging its scale for operational efficiency and negotiating power with payers. The current investor narrative centers on the stock's significant underperformance relative to the broader market, driven by concerns over regulatory headwinds, patient insurance mix pressures as highlighted by recent industry commentary, and a sharp technical sell-off, which contrasts with the company's reported strong operational trends and shareholder returns.…
HCA
HCA Healthcare
$372.13
Related headlines
Investment Opinion: Should I buy HCA Today?
Rating & Thesis: HCA is rated a Hold. The core thesis is that while the stock appears fundamentally undervalued with a forward P/E of 10.9x and strong cash flow, severe technical damage, high leverage, and clear industry headwinds create significant near-term uncertainty that outweighs the value proposition, warranting a cautious stance until these pressures show signs of abating.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The forward P/E of 10.92x is compelling for a company with a 9.6% net margin, 2) TTM free cash flow of $7.69 billion is robust, 3) Revenue continues to grow at a 6.7% YoY pace, and 4) The stock trades just 5.7% above its 52-week low, suggesting much bad news is priced in. However, this is counterbalanced by a 32% three-month decline, a high beta of 1.19, and a negative debt-to-equity ratio of -8.33.
Risks & Conditions: The two biggest risks are a breakdown below the $330 technical support level and a confirmed deterioration in payer mix leading to an earnings guidance cut. This Hold would upgrade to a Buy if the stock stabilizes above $330 and shows sequential improvement in operating margins, or if the forward P/E compresses further toward 9x. It would downgrade to a Sell on a confirmed break below $330 on high volume or if quarterly revenue growth decelerates below 5%. Relative to its own history and the current industry climate, the stock is fairly valued, reflecting a balance between its strong fundamentals and the clear near-term risks.
Sign up to view all
HCA 12-Month Price Forecast
The AI assessment is neutral with medium confidence. HCA presents a classic battleground stock: compelling valuation and cash flow versus clear technical and fundamental headwinds. The forward P/E of 10.9x is inexpensive, but justified given the decelerating revenue growth and high financial leverage. The stance would upgrade to bullish on evidence of margin stabilization and a successful defense of the $330 support level. It would turn bearish on a confirmed break below $330 or a guidance cut, either of which would signal the bear case is unfolding.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Healthcare's 12-month outlook, with a consensus price target around $483.77 and implied upside of +30.0% versus the current price.
Average Target
$483.77
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$298 - $484
Analyst target range
Analyst coverage for HCA appears limited in the provided dataset, with only 6 analysts contributing to estimates for revenue and EPS, but no consensus price target or recommendation breakdown is supplied. The wide range between the low EPS estimate of $48.68 and the high of $50.87 signals some degree of uncertainty or modeling divergence among the covering analysts. Given the absence of a consensus price target and the minimal number of analysts cited, institutional coverage can be characterized as insufficient for deriving a strong market signal, which for a company of HCA's size may indicate heightened volatility and less efficient price discovery amid the current sell-off.
Bulls vs Bears: HCA Investment Factors
The evidence currently favors the bearish thesis, driven by severe technical breakdown, industry-wide headwinds, and high financial leverage that have triggered a 32% three-month sell-off. However, the bullish case is supported by the company's fundamental strength, including robust profitability, massive cash generation, and a forward P/E of 10.9x that appears to discount significant pessimism. The single most important tension in the investment debate is whether HCA's dominant scale and operational efficiency can overcome the systemic pressures of unfavorable patient insurance mix and regulatory uncertainty. The resolution of this industry-wide headwind will be the primary determinant of whether the stock's current valuation represents a deep value opportunity or a value trap.
Bullish
- Strong Profitability & Cash Flow: HCA maintains robust profitability with a Q4 2025 net margin of 9.62% and a gross margin of 41.9%. The company generates massive free cash flow of $7.69 billion TTM, providing ample liquidity for shareholder returns and debt service.
- Attractive Forward Valuation: The stock trades at a forward P/E of 10.92x, a significant discount to its trailing P/E of 15.88x. This low forward multiple suggests the market has priced in significant pessimism, offering a potential value entry point.
- Dominant Market Leader with Scale: As the largest for-profit hospital operator with 190 hospitals and 2,500+ sites, HCA possesses significant scale advantages in operational efficiency and payer negotiations. This entrenched market position provides a durable competitive moat.
- Positive Revenue Growth Trajectory: Despite deceleration, Q4 2025 revenue grew 6.7% year-over-year to $19.51 billion. This demonstrates the underlying demand for its services is still expanding, albeit at a slower pace than previous quarters.
Bearish
- Severe Technical Downtrend & Underperformance: HCA has underperformed the S&P 500 by 44.69% over three months, with a 1-month relative strength of -20.22%. The stock is in a clear downtrend with a beta of 1.19, amplifying its downside volatility in a risk-off market.
- Industry-Wide Patient Mix Headwinds: Recent industry news highlights unfavorable patient insurance mix as a revenue headwind, as evidenced by peer Tenet Healthcare's Q1 sales miss. This indicates systemic pressure on hospital operators' payer mix and pricing power.
- High Financial Leverage & Tight Liquidity: The balance sheet shows significant leverage with a negative debt-to-equity ratio of -8.33 and a concerning current ratio of 0.83. This high debt load increases financial risk, especially in a rising interest rate environment.
- Revenue Growth Deceleration: While still positive, Q4 2025 revenue growth of 6.7% represents a slowdown from higher rates earlier in the year. This deceleration may signal underlying operational challenges or market saturation in key geographies.
HCA Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 32.09% over the past three months and 25.66% over six months, culminating in a 1-year loss of 5.20% that starkly underperforms the S&P 500's 27.04% gain. With a current price of $361.83, HCA is trading at just 5.7% above its 52-week low of $330, positioning it deep within the lower end of its annual range and signaling severe bearish momentum and potential oversold conditions. Recent momentum is decisively negative, with a 15.62% drop over the past month, which accelerates the longer-term downtrend and indicates no signs of a near-term reversal; this is further evidenced by a 1-month relative strength of -20.22% against the market, showing significant underperformance. Key technical support is clearly defined at the 52-week low of $330, while resistance lies far above at the 52-week high of $556.52; a breakdown below $330 would signal a continuation of the bearish trend, whereas any recovery would need to contend with substantial overhead supply. The stock's beta of 1.19 indicates it is 19% more volatile than the broader market, which has amplified its downside during this sell-off and is a critical factor for risk-aware investors.
Beta
1.13
1.13x market volatility
Max Drawdown
-33.6%
Largest decline past year
52-Week Range
$330-$557
Price range past year
Annual Return
-2.5%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | -13.3% | -0.0% |
| 3m | -30.2% | +8.7% |
| 6m | -23.5% | +8.0% |
| 1y | -2.5% | +23.1% |
| ytd | -20.9% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
Revenue growth remains positive but has shown signs of deceleration; the most recent Q4 2025 revenue was $19.51 billion, representing a 6.7% year-over-year increase, yet this marks a slowdown from the higher growth rates seen in prior quarters of 2025. The company is highly profitable, with Q4 2025 net income of $1.88 billion and a net margin of 9.62%, supported by a robust gross margin of 41.9%; however, the operating margin of 15.88% for the quarter indicates some pressure from rising operating expenses amidst the revenue growth. Financially, HCA generates substantial cash flow, with trailing twelve-month free cash flow of $7.69 billion, providing ample liquidity for shareholder returns and debt service, though the balance sheet carries significant leverage as indicated by a negative debt-to-equity ratio of -8.33 and a current ratio of 0.83, which points to a high debt load and relatively tight short-term liquidity.
Quarterly Revenue
$19.5B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Given HCA's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock currently trades at a trailing PE of 15.88x and a forward PE of 10.92x, with the forward multiple's discount implying the market expects earnings growth to decelerate or faces near-term headwinds. Compared to sector averages, HCA's trailing PE of 15.88x appears reasonable for a profitable healthcare services company, though specific industry average data is not provided in the valuation dataset for a precise premium/discount calculation. Historically, the stock's own trailing PE has fluctuated significantly, with a recent reading of 14.34x at the end of Q4 2025; the current multiple of 15.88x sits above this recent level but is well below historical highs seen in prior years, such as the 20.79x in Q3 2024, suggesting the valuation has compressed but may not yet be at trough levels relative to its own history.
PE
15.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HCA carries substantial financial risk, evidenced by a negative debt-to-equity ratio of -8.33 and a tight current ratio of 0.83, indicating high leverage and constrained short-term liquidity. While the company generates strong free cash flow ($7.69B TTM), this cash is needed to service its significant debt burden. Furthermore, revenue growth decelerated to 6.7% YoY in Q4 2025, raising concerns about its ability to maintain top-line momentum amidst industry headwinds, which could pressure its ability to sustain current profitability margins.
Market & Competitive Risks: The stock's valuation has compressed, with its trailing P/E of 15.88x sitting below its historical high of 20.79x from Q3 2024, but the primary risk is further multiple contraction if industry headwinds persist. The beta of 1.19 means HCA is 19% more volatile than the market, amplifying downside during sector-wide sell-offs. Competitive and regulatory risks are heightened, as recent news from Tenet Healthcare explicitly blames 'unfavorable patient insurance mix' for soft sales, a headwind that likely impacts HCA as well and could lead to sustained margin pressure.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current technical breakdown below the key $330 support level, coupled with a material deterioration in payer mix that leads to an earnings miss and a credit rating review due to its high leverage. This could trigger a cascade of analyst downgrades and forced selling. Realistic downside could see the stock re-test and break its 52-week low of $330, representing a potential loss of approximately -9% from the current price of $361.83, with further declines possible if sentiment turns decisively negative, potentially approaching the -33.63% max drawdown level observed in the recent past.
FAQ
The key risks are: 1) Financial Risk: High leverage with a negative debt-to-equity ratio of -8.33 and tight liquidity (Current Ratio: 0.83). 2) Industry/Macro Risk: Unfavorable patient insurance mix pressure, as highlighted by recent peer commentary, which could compress margins. The stock's beta of 1.19 also makes it sensitive to broader market downturns. 3) Technical Risk: The stock is in a severe downtrend, down 32% in three months, with key support at $330; a break lower could trigger further selling. The high short ratio of 3.53 indicates significant bearish sentiment.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $380-$450 as headwinds persist but stabilize. The Bull Case (25% probability) targets $500-$556 on a mean reversion rally if operational trends improve. The Bear Case (20% probability) warns of a drop to $300-$330 if industry pressures intensify and technical support fails. The most likely outcome is the Base Case, which assumes HCA's strong cash flow and market position allow it to navigate current challenges without a material deterioration in fundamentals.
Based on earnings, HCA appears undervalued. Its forward P/E of 10.92x is a steep discount to its trailing P/E of 15.88x and well below its historical high of 20.79x. The PEG ratio of 0.56 also suggests the stock is cheap relative to its growth rate. However, this low multiple reflects market concerns over decelerating revenue growth (6.7% in Q4) and high financial leverage. The valuation implies the market expects earnings growth to slow or face further pressure, making it fairly valued relative to the current risk profile.
HCA is a speculative buy only for risk-tolerant, value-oriented investors at current levels. The forward P/E of 10.9x and proximity to the 52-week low ($330 vs. $361.83) suggest significant pessimism is priced in. However, with a 32% three-month decline, high leverage (Debt/Equity: -8.33), and clear industry headwinds, it carries substantial near-term risk. It could be a good buy for those believing the headwinds are temporary and the company's scale will prevail, but it is not suitable for conservative portfolios.
HCA is more suitable for a long-term investment horizon of 3+ years. While the stock is oversold and could see a short-term bounce, the high volatility (beta 1.19), cyclical nature of the business, and need to work through industry headwinds require patience. The company's scale and cash flow generation support a long-term thesis, but near-term price action is likely to be choppy and driven by quarterly earnings and payer mix updates. It is not recommended for short-term trading due to its elevated risk and lack of clear near-term positive catalysts.